Journal
SCIENCE
Volume 352, Issue 6291, Pages 1337-1341Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aaf2288
Keywords
-
Categories
Funding
- Dutch Cancer Society Queen Wilhelmina Award [NKI 2013-6122]
- EU H2020 project APERIM
- K. G. Jebsen Foundation
- Research Council of Norway, Regional Authorities South-Eastern Norway
- University of Oslo
- Oslo University Hospital
- Norwegian Cancer Society
Ask authors/readers for more resources
Accumulating evidence suggests that clinically efficacious cancer immunotherapies are driven by T cell reactivity against DNA mutation -derived neoantigens. However, among the large number of predicted neoantigens, only a minority is recognized by autologous patient T cells, and strategies to broaden neoantigen-specific T cell responses are therefore attractive. We found that naive T cell repertoires of healthy blood donors provide a source of neoantigen-specific T cells, responding to 11 of 57 predicted human leukocyte antigen (HLA)-A*02:01-binding epitopes from three patients. Many of the T cell reactivities involved epitopes that in vivo were neglected by patient autologous tumor -infiltrating lymphocytes. Finally, T cells redirected with T cell receptors identified from donor -derived T cells efficiently recognized patient -derived melanoma cells harboring the relevant mutations, providing a rationale for the use of such outsourced immune responses in cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available